The content on this site is intended for healthcare professionals only
Dr Endres talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about toll like receptor 7 agonists for cancer immunotherapy
Toll like receptor 7 (TLR7) is from a class of proteins that play a key role in the innate immune system.
One approach is to combine TLR7 RNA with a chemical from the triphosphate group, inducing interferon and alpha helping the immune system to fight tumour cells.
Dr Endres covers the different approaches for activating the patient's own immune system to fight cancer.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma
PD-1–refractory advanced melanoma: how do we get to the finish line?
Highlights in melanoma from ASCO 2024
Melanoma outcomes improved by dual immunotherapy before surgery rather than after
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma
OncoAlert round up July 28th to August 3rd, 2023
